
Lam Research Corporation (LRCX), a large-cap growth stock in the Semiconductors industry, has received an 86% rating from Validea's Patient Investor model, which is based on Warren Buffett's long-term, value-oriented investment strategy. This high score, indicating 'some interest,' suggests LRCX exhibits strong underlying fundamentals consistent with predictable profitability, low debt, and reasonable valuations, despite a 'Fail' on Return on Total Capital. The assessment highlights LRCX's appeal to investors seeking durable businesses with sound financial characteristics.
Lam Research Corporation (LRCX), a large-cap growth stock in the semiconductor industry, scores a high 86% on Validea's Patient Investor model, which is based on the investment principles of Warren Buffett. This rating indicates a favorable alignment with criteria focused on long-term, predictable profitability and low debt at a reasonable valuation. The company successfully passed eight key fundamental tests, including Earnings Predictability, Debt Service, Free Cash Flow, and Share Repurchase, signaling strong operational health and a commitment to shareholder returns. However, the analysis also flags a notable weakness, as LRCX failed the test for Return on Total Capital. Despite this single point of failure, the predominantly positive results and the high overall score reflect a fundamentally sound profile according to this specific quantitative screen.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request a DemoOverall Sentiment
strongly positive
Sentiment Score
0.65
Ticker Sentiment